Pet therapeutic company Nexvet files for a $60 million IPO – Nasdaq

By Renaissance Capital,  December 30, 2014
Link here.

Nexvet, which is developing biologics for the treatment of pain and inflammation in cats and dogs, filed on Tuesday with the SEC to raise up to $60 million in an initial public offering. The Dublin, Ireland-based company, which was founded in 2010, plans to list on the NASDAQ under the symbol NVET. Nexvet initially filed confidentially on September 5, 2014. BofA Merrill Lynch and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Pet therapeutic company Nexvet files for a $60 million IPO originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.